Free tool
FAERS Monitor: Reyvow
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211280 or its brand name (Reyvow, Lasmiditan Succinate). Reports on generic versions are filed under their own applications.
Reports
1,163
Serious
206
18% of reports
Hospitalization
63
Death reported
13
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness210
- drug ineffective137
- feeling abnormal118
- somnolence109
- migraine89
- nausea86
- sedation79
- fatigue68
- headache66
- paraesthesia58
- hallucination44
- hypoaesthesia31
- insomnia31
- serotonin syndrome28
- euphoric mood27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 334 |
| 2021 | 398 |
| 2022 | 128 |
| 2023 | 83 |
| 2024 | 95 |
| 2025 | 75 |
| 2026 | 50 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,996 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sedationSignal | 79 | 54.7 | 44.2 | 4,105 |
| euphoric moodSignal | 27 | 47.8 | 32.9 | 1,188 |
| serotonin syndromeSignal | 28 | 26.4 | 18.3 | 659 |
| migraineSignal | 89 | 16.9 | 13.8 | 1,318 |
| hallucinationSignal | 44 | 10.6 | 7.9 | 373 |
| somnolenceSignal | 109 | 9.8 | 8.2 | 860 |
| feeling abnormalSignal | 118 | 8.9 | 7.5 | 830 |
| dizzinessSignal | 210 | 7.6 | 6.7 | 1,229 |
| paraesthesiaSignal | 58 | 6.7 | 5.2 | 276 |
| hypoaesthesiaSignal | 31 | 3.7 | 2.6 | 60 |
| insomniaSignal | 31 | 2.1 | 1.5 | 17 |
| nausea | 86 | 2.0 | 1.6 | 41 |
| headache | 66 | 1.9 | 1.5 | 28 |
| drug ineffective | 137 | 1.9 | 1.6 | 59 |
| fatigue | 68 | 1.6 | 1.3 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.